Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / MPZL2

MPZL2

Basics

Aliases:
This biomarker is also known as:
  • Epithelial V-like antigen 1,
  • myelin protein zero-like 2,
  • EVA,
  • O60487,
  • epithelial V-like antigen 1,
  • myelin protein zero-like protein 2,
  • EVA1,

View in BioMuta

Description…

The EVA1, or MPZL2 gene is expressed in the thymus and in several epithelial structures early in embryogenesis. The protein MPZL2 displays an ability to mediate cell adhesion through a homophilic interaction, and its selective regulation by T cell maturation might imply the participation of MPZL2 in the earliest phases of thymus organogenesis. Two transcript variants encoding the same protein have been found for this gene.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

No additional ovarian data available.

Performance Comment

MPZL2 (EVA1) was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. EVA1 was not in the group of 13 selected for further validation.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 03/06/2014

Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.

Announcement